Unlocking the potential of psychedelics as medicine: Past obstacles and future outlooks
Sharon Kim, Rayven-Nikkita Collins, Jimmy Teng, Leanna Kalinowski
MIT Science Policy Review August 31, 2023 DOI: 10.38105/spr.osqbpecncp (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | Argues that while clinical studies indicate psychedelics have therapeutic potential in psychiatry and possibly other areas of medicine, understanding remains nascent, and that historical stigma and legal and regulatory barriers have hindered rigorous research. The authors contend that growing policy initiatives to improve access raise important ethical, public safety, healthcare access, and equity implications. |
Abstract
Psychedelic compounds are known to exert profound effects on the mind and have been used by humanity for centuries. In recent years, there has been a resurgence of interest in the therapeutic potential of these compounds, particularly when integrated with psychotherapy, to treat psychiatric conditions. Psychedelics may also have the potential to drive transformative advancements in the field of medicine, transcending the boundaries of psychiatry. This resurgence in interest can be attributed to a series of clinical studies that have showcased the compounds’ therapeutic effects, safety profiles, and mechanisms of action. Yet, our understanding of the medicinal potential of psychedelics is still in its nascent stages. The historically negative perceptions of these substances, along with legal and regulatory obstacles, have posed challenges for researchers and institutions seeking to conduct rigorous scientific studies. Nevertheless, in recent years, there has been a growing shift in attitudes and increased interest in unlocking the therapeutic potential of these compounds, prompting a reevaluation of their role in medical research and treatment. Now, policies and initiatives designed to enhance access to these substances have important ethical, public safety, healthcare access, and equity implications. This review seeks to provide an overview of psychedelics while delving into funding trends, policies, and initiatives poised to drive the field toward new horizons.
Citations in the library
Cites 37
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
and 32 more in the library